Lazar Popovic/LinkedIn
Apr 25, 2025, 15:07
Lazar Popovic: Treatment sequencing in metastatic HR+/HER2− Breast Cancer
Lazar Popovic, Professor of Oncology at the University of Novi Sad, posted on LinkedIn, about recent paper he and his colleagues co-authored:
“The standards of treatment in oncology are changing day by day.
This is especially true when it comes to the treatment of breast cancer. In the last few years, a whole series of treatments have appeared in HR+/HER- metastatic breast cancer that prolong the life and maintain quality of life of the patients.
Due to the large number of innovative therapies, the problem of sequencing therapeutic options has arisen. Also, there has been a need for biomarker testing that is mandatory with certain drugs.
Therefore, we have published a paper in the journal Cancers that aims to help colleagues in choosing the best therapeutic options and diagnostic test for their patients with HR+HER – mBC.
You can find a paper on.”
Title: Treatment Sequencing in Metastatic HR+/HER2− Breast Cancer: A Delphi Consensus
Authors: Lazar Popovic, Simona Borštnar, et al.
Journal: Cancers, April 2025
More posts featuring Lazar Popovic.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 25, 2025, 15:07
Apr 25, 2025, 15:00
Apr 25, 2025, 14:32
Apr 25, 2025, 14:10
Apr 25, 2025, 13:40
Apr 25, 2025, 13:35
Apr 25, 2025, 13:27
Apr 25, 2025, 13:27
Apr 25, 2025, 13:26